(Q45065765)

9 December 2017

Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure (English)

1 reference

9 December 2017

1 reference

5

Carl Blomqvist

1 reference

9 December 2017

6

Inkeri Elomaa

1 reference

9 December 2017

Leena Vehmanen

1

1 reference

9 December 2017

Tiina Saarto

series ordinal

2

1 reference

9 December 2017

Juha Risteli

series ordinal

3

1 reference

9 December 2017

Leila Risteli

series ordinal

4

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Breast Cancer Research and Treatment

9 December 2017

1 reference

9 December 2017

87

1 reference

9 December 2017

2

1 reference

9 December 2017

181-188

1 reference

https://scigraph.springernature.com/pub.10.1023/b:brea.0000041624.00665.4e

9 December 2017

0 references

cites work

Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

Relative contributions of aging and estrogen deficiency to postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Influence of early age at menopause on vertebral bone mass

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Controlled Clinical Study on the Use of Dichloromethylene Diphosphonate in Patients with Breast Carcinoma Metastasizing to the Skeleton

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Acute effects of bisphosphonates on new and traditional markers of bone resorption.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000041624.00665.4E

7 January 2021

10.1023/B:BREA.0000041624.00665.4E

Identifiers

DOI

1 reference

Dimensions Publication ID

9 December 2017

0 references

1 reference